Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
By T. Ley, C. Miller, L. Ding, Benjamin J. Raphael, A. Mungall, A. G. Robertson, Katherine A. Hoadley, Timothy Triche, Peter W. Laird, J. Baty and 90 more. New England Journal of Medicine, 2013
4,584 citations recorded by the source corpus.
BACKGROUND Many mutations that contribute to the pathogenesis of acute myeloid leukemia (AML) are undefined. The relationships between patterns of mutations and epigenetic phenotypes are not yet clear. METHODS We analyzed the genomes of 200 clinically annotated adult cases of de novo AML, using either whole-genome sequencing (50 cases) or whole-exome sequencing (150 cases), along with RNA and microRNA sequencing and DNA-methylation analysis. RESULTS AML genomes have fewer mutations than most other adult cancers, with an average of only 13 mutations found in genes. Of these, an average of 5 are in genes that are recurrently mutated in AML. A total of 23 genes were significantly mutated, and another 237 were mutated in two or more samples. Nearly all samples had at least 1 nonsynonymous mutation in one of nine categories of genes that are almost certainly relevant for pathogenesis, including transcription-factor fusions (18% of cases), the gene encoding nucleophosmin (NPM1) (27%), tumor-suppressor genes (16%), DNA-methylation–related genes (44%), signaling genes (59%), chromatin-modifying genes (30%), myeloid transcription-factor genes (22%), cohesin-complex genes (13%), and spliceosome-complex genes (14%). Patterns of cooperation and mutual exclusivity suggested strong biologic relationships among several of the genes and categories. CONCLUSIONS We identified at least one potential driver mutation in nearly all AML samples and found that a complex interplay of genetic events contributes to AML pathogenesis in individual patients. The databases from this study are widely available to serve as a foundation for further investigations of AML pathogenesis, classification, and risk stratification. (Funded by the National Institutes of Health.)
Subfields: Genetics, Hematology, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/6457feeb215ab59e6588fd0073aca689f65eecf1
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Genetics
In Hematology
In Molecular Biology
Citations in the corpus
- R-2HG Exhibits Anti-tumor Activity by Targeting FTO/m6A/MYC/CEBPA Signaling (2017, methodology): “To address this question, we conducted integrative analysis of the TCGA AML microarray dataset (Ley et al., 2013) with our RNA-seq data shown in Figure 2A.”
- ABySS 2.0: resource-efficient assembly of large genomes using a Bloom filter (2016, neutral): “Although this enabling technology found applications in many large cancer cohort studies (Yip et al. 2011; Roberts et al. 2012; Pugh et al. 2013; Ley et al. 2013; Morin et al. 2013), its large memory footprint constituted a substantial bottleneck.”